• ETS1–SENP2–FUNDC1 Axis in Bronchopulmonary Dysplasia

  2026-09-22

  The reference study identifies ETS1 as an upstream regulator of mitochondrial quality control in bronchopulmonary dysplasia, linking transcriptional activation of SENP2 to SUMO1-dependent FUNDC1 degradation and suppression of excessive mitophagy. Its cell and mouse hyperoxia models suggest that the ETS1–SENP2–HSPA8–FUNDC1 pathway may preserve mitochondrial homeostasis and alveolar development, although additional validation is needed before clinical translation.

• Gefitinib (ZD1839) for Reliable EGFR Assays

  2026-09-22

  This scenario-driven guide explains how Gefitinib (ZD1839), SKU A8219, can improve the interpretation and reproducibility of EGFR-focused viability, proliferation, and cytotoxicity experiments. It covers assay design, stock preparation, orthogonal validation, cross-domain applications, and practical supplier-selection criteria.

• Parathyroid hormone (1-34) (human): Lab Guide

  2026-09-21

  This scenario-based guide explains how Parathyroid hormone (1-34) (human), SKU A1129, can support controlled bone, kidney, viability, and signaling experiments. It translates receptor potency, formulation, storage, and assay-interpretation data into practical decisions for biomedical laboratories.

• Catalpol: Liver Injury Assay & Workflow Guide

  2026-09-21

  Build a mechanism-led Catalpol workflow for drug-induced liver injury, combining glucose metabolism, mitochondrial respiration, oxidative stress, and SIRT1/HIF-1α assays. The approach distinguishes pathway rescue from nonspecific cytoprotection and can be adapted cautiously to broader Catalpinoside research applications.

• HDAC Inhibition Reverses EBV-Driven NPC Dedifferentiation

  2026-09-20

  The reference study identifies an epigenetic mechanism by which EBV latent protein LMP1 drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma. It further shows that HDAC inhibition can restore CEBPA expression and differentiation in preclinical models, supporting a mechanistically grounded form of differentiation therapy for solid tumors.

• Erlotinib as a State-Resolved EGFR Probe

  2026-09-19

  Erlotinib, also known as NSC 718781, can do more than suppress EGFR activity: it can help distinguish receptor-proximal dependence from SCUBE3-associated resistance and immune-evasion biology. This article presents an evidence-aware assay framework for interpreting kinase, proliferation, apoptosis, DNA-repair, and tumor-microenvironment readouts.

• BMS 599626 dihydrochloride Workflow Guide

  2026-09-18

  Build a rigorous EGFR/HER2 workflow around BMS 599626 dihydrochloride, from receptor phosphorylation assays to cancer cell proliferation inhibition and xenograft-oriented study design. The guide also shows how to connect pathway perturbation with senescence assays without overstating evidence for senolytic activity.

• Recombinant Human EGF for 3D Glioblastoma Assays

  2026-09-18

  Use recombinant human EGF to add a defined growth-factor variable to 3D glioblastoma spheroid experiments, from stemness screening to dose-response studies. This workflow combines validated EGF bioactivity with a streamlined 96-well assay that reduces handling, time, and contamination risk.

• Gefitinib in Gastric Cancer Assembloid Research

  2026-09-17

  Discover how Gefitinib (ZD1839) can be evaluated in patient-derived gastric cancer assembloids rather than epithelial monocultures alone. This guide connects EGFR pathway pharmacology with stromal effects, phosphosignaling, viability, apoptosis, and assay design.

• CXCR4-EGFR Heteromers and Ligand-Dependent Signaling

  2026-09-17

  Comez et al. show that CXCR4 and EGFR assemble into oligomeric signaling complexes whose conformation and coupling to Gi proteins, PLCγ, and β-arrestin-2 change with receptor activation. NanoBRET and nanobody-based proximity ligation assays extend this finding from transfected cells to native HeLa cells, providing a framework for interpreting receptor co-expression in cancer.

• 3D Tumor Spheroids for Glioblastoma Stemness

  2026-09-16

  Chen and colleagues present a streamlined 96-well 3D-tumor spheroid assay for functionally assessing stem-like behavior in glioblastoma cell lines. By replacing a slower two-round sphere-forming workflow with a single-round format, the protocol reduces handling and contamination opportunities while supporting mechanistic studies and higher-throughput screening.

• SAG Exposure Disrupts Embryonic Tongue Development

  2026-09-16

  A 2025 Developmental Biology study shows that embryonic exposure to the Smoothened receptor agonist SAG disrupts mouse tongue morphogenesis by suppressing proliferation, altering muscle development, and reducing TGF-β2 expression. The work provides a pharmacological model of cleft tongue formation and emphasizes that excessive Hedgehog pathway activation can be as disruptive as pathway deficiency during craniofacial development.

• OTUB1–DHODH Axis in Gemcitabine Resistance

  2026-09-15

  A 2025 Cell Death and Disease study identifies OTUB1 as a regulator of gemcitabine resistance in pancreatic cancer by stabilizing a DDX3X–DHODH mRNA axis and sustaining de novo pyrimidine synthesis. The findings connect deubiquitylation, RNA stability, and metabolic adaptation, supporting OTUB1 inhibition as a strategy for sensitizing high-OTUB1 tumors to gemcitabine.

• EphA2 Synthetic Lethality in MYC-Driven TNBC

  2026-09-15

  A 2026 pre-proof study used a chemogenetic screen of approximately 600 kinase inhibitors to identify EphA2 inhibition as a selective vulnerability in MYC-driven triple-negative breast cancer. The lead compound ALW-II-41-27 triggered p53-independent intrinsic apoptosis and reduced growth of two TNBC xenograft models, supporting EPHA2 as a candidate synthetic-lethal partner of MYC.

• Dihydrotestosterone: Applied Research Workflows

  2026-09-14

  Dihydrotestosterone (DHT) provides a defined androgen receptor stimulus for studying EGFR–ERBB2 signaling in bladder cancer, androgen-responsive prostate assays, and neuromuscular disease models. This workflow-focused guide connects concentration-controlled cell experiments with translational readouts while emphasizing formulation, controls, and interpretation limits.

7886 records 1/526 page Next 12345 下5页 Last page